Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 17/20 | 0.53 |
| ▸ | CTRC | Q99895 | 11/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30765589 | 0.99 | CMA1 (0.53) | CMA1CTRCNTRK1CTSGNTRK3 | |
| SCHEMBL31558453 | 0.90 | NTRK1 (0.48) | CMA1CTRCNTRK1NTRK3 | |
| SCHEMBL30766049 | 0.86 | NTRK1 (0.43) | CMA1CTRCNTRK1NTRK3 | |
| Hydrochloric Acid SCHEMBL30765434 | 0.86 | NTRK1 (0.43) | CMA1CTRCNTRK1NTRK3 | |
| SCHEMBL30765566 | 0.85 | NTRK1 (0.43) | CMA1CTRCNTRK1NTRK3 | |
| SCHEMBL30765697 | 0.84 | F2 (0.43) | CMA1CTRCNTRK1NTRK3 | |
| SCHEMBL31558568 | 0.84 | NTRK1 (0.45) | CMA1CTRCNTRK1NTRK3 | |
| SCHEMBL31558587 | 0.84 | NTRK1 (0.41) | CMA1CTRCNTRK1NTRK3 | |
| SCHEMBL30765961 | 0.82 | NTRK1 (0.43) | CMA1CTRCNTRK1NTRK3 | |
| SCHEMBL31558403 | 0.82 | NTRK1 (0.40) | CMA1CTRCNTRK1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |